Immunotherapy makes breakthrough in breast cancer

Global study shows immunotherapy, combined with chemotherapy, can help to extend lives of patients with aggressive breast cancer

In the Impassion 130 study, triple-negative breast cancer patients treated with immunotherapy and chemotherapy survived 7.2 months without the disease progressing, compared with 5.5 months in the chemotherapy- only group. PHOTO: ISTOCKPHOTO
New: Gift this subscriber-only story to your friends and family

News that combining chemotherapy with immunotherapy can help extend the lifespan of triple-negative breast cancer patients offers hope for those inflicted with this aggressive and hard-to-treat cancer.

It is a breakthrough for immunotherapy as breast cancer was thought to be unresponsive to the body's immune system.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.

A version of this article appeared in the print edition of The Straits Times on November 05, 2018, with the headline Immunotherapy makes breakthrough in breast cancer. Subscribe